Salarius Pharmaceuticals ...

NASDAQ: SLRX · Real-Time Price · USD
5.76
0.14 (2.49%)
At close: Aug 26, 2025, 3:58 PM

Salarius Pharmaceuticals Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
4.43K 4.43K 4.43K 17.89K 17.89K 17.89K 17.89K n/a n/a n/a n/a n/a n/a 571.39K 1.84M 3.32M 4.7M 5.37M
Cost of Revenue
5.53K 5.53K 5.53K 4.42K 8.93K 9.49K 10.05K 10.62K 6.67K 2.93M 7.36M 9.21M 9.21M 8.39M 5.69M 5.87M 7.66M 7.01M
Gross Profit
-1.1K -1.1K -1.1K 13.47K 8.97K 8.4K 7.84K -10.62K -6.67K -2.93M -7.36M -9.21M -9.21M -7.81M -3.85M -2.55M -2.97M -1.64M
Operating Income
-5.17M -5.68M -5.73M -5.22M -6.74M -9.25M -12.89M -18.4M -21.49M -22.28M -22.98M -20.65M -18.77M -17.13M -12.81M -10.43M -8.44M -7.04M
Interest Income
76.03K 111.38K 158.54K 222.66K 277.68K 234.6K 258.16K 169.26K 158.5K 158.5K 78.61K 78.61K n/a n/a n/a n/a n/a n/a
Pretax Income
-5.1M -5.57M -5.58M -4.99M -6.46M -8.92M -12.54M -18.03M -30M -30.84M -31.61M -29.34M -18.67M -17.03M -12.77M -10.43M -8.41M -7.12M
Net Income
-5.1M -5.57M -5.58M -4.99M -6.46M -8.92M -12.54M -18.03M -30M -30.84M -31.61M -29.34M -18.67M -17.03M -12.77M -10.43M -8.41M -7.12M
Selling & General & Admin
4.67M 5.08M 4.96M 4.56M 5.19M 5.55M 5.72M 6.6M 6.94M 7.16M 7.14M 6.8M 6.69M 6.45M 6.1M 5.87M 5.47M 5.58M
Research & Development
504.49K 602.56K 770.02K 654.63K 1.55M 3.69M 7.17M 11.8M 14.55M 15.12M 15.84M 13.85M 12.07M 11.25M 8.55M 7.88M 7.66M 7.01M
Other Expenses
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Operating Expenses
5.18M 5.68M 5.73M 5.22M 6.74M 9.25M 12.89M 18.4M 21.49M 22.28M 22.98M 20.64M 18.77M 17.7M 14.65M 11.99M 9.62M 7.17M
Interest Expense
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 1.25K 4.04K 7.27K 7.27K
Selling & Marketing Expenses
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost & Expenses
5.18M 5.68M 5.74M 5.22M 6.74M 9.25M 12.89M 18.4M 21.49M 22.28M 22.98M 20.64M 18.77M 17.7M 14.65M 13.74M 13.13M 12.59M
Income Tax Expense
n/a n/a n/a -5 -5 -5 -5 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Shares Outstanding (Basic)
142.23K 111.48K 64.47K 85.89K 40.23K 35.13K 32.98K 31.42K 22.69K 20.03K 18.83K 18.82K 17.89K 15.5K 15.15K 15.01K 14.94K 10.23K
Shares Outstanding (Diluted)
142.23K 111.48K 64.47K 85.89K 40.23K 35.13K 32.98K 31.44K 22.69K 20.03K 18.87K 18.82K 17.93K 15.5K 15.15K 15.01K 14.99K 10.23K
EPS (Basic)
-56.4 -85.2 -118.8 -122.85 -189.6 -325.8 -544.35 -560.7 -1.25K -1.35K -1.48K -1.71K -1.19K -1.13K -910.8 -683.4 -732.6 -912.6
EPS (Diluted)
-56.4 -85.2 -118.8 -122.85 -189.6 -325.8 -544.35 -560.7 -1.25K -1.35K -1.48K -1.71K -1.19K -1.13K -910.8 -683.4 -732.6 -912.6
EBITDA
-5.16M -5.67M -5.73M -5.21M -6.73M -9.24M -12.88M -18.39M -21.49M -22.27M -22.97M -20.63M -18.75M -17.11M -12.79M -10.41M -8.42M -7.09M
EBIT
-5.16M -5.67M -5.73M -5.22M -6.74M -9.25M -12.89M -18.4M -21.49M -22.28M -22.98M -20.64M -18.77M -17.13M -12.81M -10.43M -8.44M -7.04M
Depreciation & Amortization
3.32K 4.42K 4.42K 4.42K 8.93K 9.49K 10.05K 10.62K 6.67K 6.68K 9.8K 12.93K 16.06K 19.18K 19.18K 19.75K 19.18K 18.62K